KMT2A and acute myeloid leukemia: In addition, we found that the CR rate after one cycle of DAV treatment was 100% (6/6), 100% (13/13), and 100% (2/2) in patients with AML bearing a KMT2A rearrangement, RUNX1::RUNX1T1, or CBFβ::MYH11, respectively.